Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 08 2023 - 4:01PM
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company
dedicated to breaking through barriers in gene therapy and
neurology, has entered into an employment agreement with Beth
Shafer, Ph.D., M.A., M.Phil. that, among other things, provides for
the grant to Dr. Shafer of a non-qualified stock option and
restricted stock units as an inducement material to Dr. Shafer’s
entering into employment with Voyager as Voyager’s Chief Business
Officer. The inducement awards were approved by the Compensation
Committee of Voyager’s Board of Directors in accordance with Nasdaq
Stock Market Listing Rule 5635(c)(4). The option award became
effective on August 7, 2023, and the restricted stock unit award is
scheduled to become effective on October 1, 2023.
The stock option award provides for the purchase of an aggregate
of 122,000 shares of Voyager’s common stock, and the restricted
stock unit award will represent 61,000 shares of Voyager’s common
stock. The stock option has a ten-year term and an exercise price
of $8.68 per share, which is equal to the closing price of
Voyager's common stock on August 7, 2023, the effective date of
grant. The stock option vests over four years, with 25% of the
shares underlying the stock option vesting on the first anniversary
of the effective date of grant and 75% of the shares underlying the
stock option vesting in 36 equal monthly installments following the
first anniversary of the effective date of grant. The restricted
stock unit award vests annually in equal installments over three
years, beginning on the first anniversary of the effective date of
grant. Vesting of the equity awards is subject to Dr. Shafer’s
continued employment with Voyager. Each equity award is also
subject to the terms and conditions of an award agreement.
About Voyager Therapeutics Voyager
Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to
breaking through barriers in gene therapy and neurology. The
potential of both disciplines has been constrained by delivery
challenges; Voyager is leveraging cutting-edge expertise in capsid
discovery and deep neuropharmacology capabilities to address these
constraints. Voyager’s TRACER™ AAV capsid discovery platform has
generated novel capsids with high target delivery and blood-brain
barrier penetration at low doses, potentially addressing the narrow
therapeutic window associated with conventional gene therapy
delivery vectors. This platform is fueling alliances with Pfizer
Inc., Novartis Pharma AG, Neurocrine Biosciences, Inc., and Sangamo
Therapeutics, Inc., as well as multiple programs in Voyager’s own
pipeline. Voyager’s pipeline includes wholly owned and
collaborative preclinical programs in Alzheimer’s disease,
amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other
diseases of the central nervous system, with a focus on validated
targets and biomarkers to enable a path to rapid potential
proof-of-biology. For more information, visit
www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and
TRACER™ is a trademark, of Voyager Therapeutics, Inc.
InvestorsInvestors@vygr.com
MediaPeg
Rusconiprusconi@vergescientific.com
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Jul 2024 to Aug 2024
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Aug 2023 to Aug 2024